CAS: 1186426-66-3

DBPR108

DBPR108 is an orally bioavailable dipeptide-derived DPP4 inhibitor (IC50: 15 nM) and it has no inhibition on DDP8 and DPP9.

(2S,4S)-4-Fluoro-1-((2-Methyl-4-Oxo-4-(Pyrrolidin-1-Yl)Butan-2-Yl)Glycyl)Pyrrolidine-2-Carbonitrile

DPP-4 is an enzyme that inactivates the incretin hormone glucagon-like peptide-1 (GLP-1). DBPR108 is a small molecule inhibitor of DPP-4. DPP-4 inhibitors have been shown to be effective in clinical trials for type 2 diabetes, with improvements in glycaemic control and weight management. This drug has a long half life and is orally active, with a high level of protein binding. It is also chemically stable, even at high temperatures or pH levels, which means it can be used as an inhibitor drug in the treatment of other diseases.